Lapdap has been linked to reductions in hemoglobin levels in patients with a hereditary enzyme disorder that affects 10 to 25 percent of Africans. Low hemoglobin can lead to anemia which in severe cases may require a blood transfusion.

Professor Sir Alasdair Breckenridge, CBE, was most recently Professor of Clinical Pharmacology at the University of Liverpool.

He has been Chair of the Committee on Safety of Medicines (CSM) since 1999, a role which he relinquished when he became chair of the MHRA on its creation in April 2003.

The University of Liverpool has capitalised on 15 years' research by initiating a Public Private Partnership to turn promising lab results into an affordable anti-malarial treatment which can combat drug resistance in Africa.

In the 2003 University of Liverpool Annual Report there is a full page spread 'bigging up' Lapdap. The blurb reads:

Fighting malaria: Professor Peter Winstanley has led the development of a new low-cost anti-malarial drug LapdapTM, designed for sub-Saharan Africa where ‘Plasmodium falciparum’ malaria kills one to two million people every year.

It continues...

GLAXOSMITHKLINE (GSK) WILL MARKET THE AFFORDABLE NEW DRUG.
LAPDAP HAS BEEN DEVELOPED THROUGH A UNIQUE PUBLIC-PRIVATE PARTNERSHIP BETWEEN THE UNIVERSITY, THE WORLD HEALTH ORGANISATION, GSK, THE GOVERNMENT’S DEPARTMENT FOR INTERNATIONAL DEVELOPMENT (DFID), THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE AND THE LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, WITH GRANT SUPPORT FROM THE WELLCOME TRUST.

Breckenridge, along with Peter Winstanley, Stephen Ward, Robert Snow, wrote a paper entitled: Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

 1  |  2